Ken Griffin’s Apogee Therapeutics APGE Stock Holding History

Ken Griffin’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.68M	Buy	20,000 +4,200	+27%	+$305K	﹤0.01%	6470
2025 Q4	$1.19M	Buy	15,800 +8,300	+111%	+$523K	﹤0.01%	7009
2025 Q3	$298K	Buy	+7,500	New	+$286K	﹤0.01%	10387
2025 Q2	–	Sell	-20,100	Closed	-$751K	–	12420
2025 Q1	$751K	Buy	20,100 +17,500	+673%	+$677K	﹤0.01%	7589
2024 Q4	$118K	Buy	2,600 +2,100	+420%	+$107K	﹤0.01%	11221
2024 Q3	$29.4K	Sell	500 -6,900	-93%	-$331K	﹤0.01%	12461
2024 Q2	$291K	Buy	7,400 +2,300	+45%	+$112K	﹤0.01%	9203
2024 Q1	$339K	Buy	+5,100	New	+$223K	﹤0.01%	9209

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ken Griffin's APGE Position: Q1 2026 in Review

Ken Griffin reduced its Apogee Therapeutics (APGE) stake by 22% in Q1 2026, selling an estimated $12.2M and leaving 598,902 shares worth $50.4M. The position accounts for 0.01% of the portfolio, ranked #1352.

Ken Griffin first reported a position in APGE in Q3 2023 and has held it in 8 quarters since. The position peaked at $57.9M in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Ken Griffin held 598,902 shares of Apogee Therapeutics worth $50.4M as of Q1 2026.
Ken Griffin sold 168,079 Apogee Therapeutics shares in Q1 2026, an estimated $12.2M.
Apogee Therapeutics made up 0.01% of Ken Griffin's portfolio in Q1 2026, its #1352 holding.
Ken Griffin first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 8 quarters since.
Ken Griffin's Apogee Therapeutics position peaked at $57.9M in Q4 2025.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.